Paper Review Records
All Paper Review Records
17 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
149
days
Elesclomol-mediated cuproptosis overcomes cisplatin resistance by restricting epigenetically activated mitochondrial respiration: Novel therapeutic insights into cisplatin–elesclomol combination therapy
Authors
Tianyu Zhu; Yongyun Li; Jieling Tang; Huimin Lin; Xiang Gu; Shengfang Ge; Lin Ye; Pengsen Wu; Xianqun Fan; Ai Zhuang; Peiwei Chai; Renbing JiaShow moreShow less
Affiliations
State Key Laboratory of Eye Health, Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China; Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai 200011, China; Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai 200040, China; Shenzhen Eye Hospital, Shenzhen Eye Medical Center, Southern Medical University, Shenzhen 518040, ChinaShow moreShow less
84
days
CMTM6 maintains B cell-intrinsic membrane CD40 stability to regulate anti-tumor immunity
Authors
Runqiu Chen; Wenlong Chang; Fanglin Li; Longhua Gu; Chen Chen; Rong Zhang; Zhiying Li; Jianhua Sun; Jing Chen; Likun Gong; Yiru LongShow moreShow less
Affiliations
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Department of Microbiological and Biochemical Pharmacy, School of Pharmacy, Fudan University, Shanghai 201300, China; School of Public Health, China Medical University, Shenyang 110122, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, ChinaShow moreShow less
230
days
H2AC19 promotes lung adenocarcinoma progression via p300/EGR1/MMP-1-mediated angiogenesis
Authors
Fuwen Zuo; Jinlong Yu; Tong Liu; Xiaorui Liu; Jilong Yin; Pengzhong Ding; Yuhan Pang; Zhengdong Luo; Xiaofeng Wang; Ling Guo; Yirong Zhang; Shuang Qi; Lutao Du; Ziying Wang; Fan Yi; Xiaoshi ZhangShow moreShow less
Affiliations
Department of Clinical Laboratory, National Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital of Shandong University, Jinan 250012, China; Department of Pharmacology, School of Basic Medical Sciences, Shandong University, Jinan 250012, China; Department of Clinical Pharmacology, The Second Hospital of Shandong University, Jinan 250033, China; Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan 250012, China; Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China; School of Chinese Language and Literature, Shandong Normal University, Jinan 250014, China; Shandong Center for Food and Drug Evaruation and Inspection, Jinan 250014, ChinaShow moreShow less
344
days
A novel small molecule inhibitor targeting KHSRP methylation suppresses colon cancer progression
Authors
Shuang Chen; Ningjing Zhang; Yuxiao Zhang; Jiebin Fang; Zhen Tang; Dashan Zhang; Xinyi Tang; Yalin Yu; Mengde Xia; Yan Yi; Wanjing Ding; Zhongjun MaShow moreShow less
Affiliations
Hainan Institute, Zhejiang University, Sanya 572025, China; Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China; School of Life Sciences, Westlake University, Hangzhou 310000, China; Center of Synthetic Biology and Integrated Bioengineering, Westlake University, Hangzhou 310000, ChinaShow moreShow less
180
days
Targeting SIRT6 epigenetically restrains neutrophil hyperplasia and enhances chemotherapeutic efficacy
Authors
Luping Wang; Xiaoqian Wu; Panxia Wang; Minshan Zhang; Li Li; Zhenhan Huang; Yang Mao; Haoming Chen; Qin Wen; Wei Liu; Zhibin Huang; Feifei Li; Juan ShenShow moreShow less
Affiliations
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China; The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou 510006, China; School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China; Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, ChinaShow moreShow less
231
days
Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy
Authors
Hong Toan Lai; Daniela Dias-Pedroso; Maria Eugénia Marques Da Costa; Romain Fernandes; Tran Ngoc Anh Nguyen; Olivia Bawa; Pierre Khneisser; João Gabriel Silva; Yassine Khalij; Michelangelo Campanella; John Griffith Jones; Svetlana Dokudovskaya; Guido Kroemer; Antonin Marchais; Nathalie Gaspar; Birgit Geoerger; Oumar Diane; Liuba Mazzanti; Tâp Ha Duong; Guy Lewin; Laurent Ferrié; Bruno Figadère; Catherine BrennerShow moreShow less
Affiliations
CNRS, Institut Gustave Roussy, Biologie du cancer et métabolisme, Université Paris-Saclay, Villejuif 94805, France; INSERM UMR 1015, Gustave Roussy Cancer Campus, Villejuif 94805, France; INSERM US23, CNRS UAR 3655, AMMICa, Experimental and Translational Pathology Platform, Gustave Roussy, Villejuif 94805, France; Department of Pathology, Gustave Roussy Cancer Campus, Villejuif 94805, France; Université Paris-Saclay, Institut Gustave Roussy, Inserm, Immunologie anti-tumorale et immunothérapie des cancers, Villejuif 94805, France; Centre for Innovative Biomedicine and Biotechnology, and III-UC-Institute of Interdisciplinary Research, University of Coimbra, Coimbra 3004-504, Portugal; Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris 75006, France; Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif 94805, France; Institut du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris 75015, France; Department of Oncology for child and adolescent, Gustave Roussy, Villejuif 94805, France; BioCIS, CNRS, Université Paris-Saclay, Orsay 91400, FranceShow moreShow less
FAQ
How long does Acta Pharmaceutica Sinica B take to review a manuscript?
As of 2026-11-19, CrushSCI has 17 complete review records for Acta Pharmaceutica Sinica B. The fastest paper went from submission to acceptance in 49 days (Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota andl-serine metabolic pathway, received 2025-10-09, accepted 2025-11-27); the slowest took 344 days. The average is 179.6 days and the median is 162 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
